• Facets (new session)
• Description
• Metadata
• Settings
  • Rule: ActivityStreamsMapasEquivalentb3sb3sifpdbprdf-labelfacetshttp://dbpedia.org/resource/inference/rules/dbpedia#http://dbpedia.org/resource/inference/rules/opencyc#http://dbpedia.org/resource/inference/rules/umbel#http://dbpedia.org/resource/inference/rules/yago#http://dbpedia.org/schema/property_rules#http://www.ontologyportal.org/inference/rules/SUMO#http://www.ontologyportal.org/inference/rules/WordNet#http://www.w3.org/2002/07/owl#ldpoplwebskos-transurn:det:rdf:labelvirtrdf-labelvirtrdf-urlNone
    
  • Inverse Functional Properties: Disabled (fastest) Apply to subjects only Apply to objects only Apply to both subjects and objects
  • "Same As": Disabled (fastest) Apply to subjects only Apply to objects only Apply to both subjects and objects (recommended) Apply to subjects, objects and predicates (not recommended on big datasets) Apply to predicates only (special use cases only)

About: Cynapsus Therapeutics     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : yago:WikicatPharmaceuticalCompaniesOfCanada, within Data Space : dbpedia.demo.openlinksw.com associated with source document(s)

Type: Thingcompanyschema:Organizationdul:Agentdul:SocialPersonagentwikidata:Q24229398OrganizationBusiness enterpriseyago:WikicatCompaniesBasedInTorontoyago:WikicatCompaniesListedOnTheTSXVentureExchangeyago:Abstraction100002137yago:Company108058098yago:DrugCompany108002578yago:Group100031264yago:Institution108053576yago:Organization108008335yago:YagoLegalActoryago:YagoLegalActorGeoyago:YagoPermanentlyLocatedEntityorganisationyago:SocialGroup107950920yago:WikicatPharmaceuticalCompaniesOfCanada New Facet based on Instances of this Class

Cynapsus Therapeutics Inc. is a specialty pharmaceutical company developing a drug to treat the motor symptoms of Parkinson's disease. Based in Toronto, Ontario, Canada. Formerly named Cannasat Therapeutics they changed their name to Cynapsus Therapeutics in 2010. In September 2016, Sunovion (a subsidiary of Dainippon Sumitomo Pharma) announced it would acquire Cynapsus Therapeutics for approximately $624 million.